Comparative Pharmacology
Head-to-head clinical analysis: GLYXAMBI versus STEGLATRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYXAMBI versus STEGLATRO.
GLYXAMBI vs STEGLATRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLYXAMBI is a combination of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin increases incretin hormones (GLP-1, GIP), enhancing insulin release and decreasing glucagon levels in a glucose-dependent manner.
Steglatro (ertugliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose.
10 mg/5 mg orally once daily (empagliflozin/linagliptin). May increase to 25 mg/5 mg once daily if tolerated.
0.5 mg orally once daily for patients with type 2 diabetes; no dose adjustment for age, gender, or race.
None Documented
None Documented
Empagliflozin: Terminal half-life ~12.4 hours allows once-daily dosing. Linagliptin: Terminal half-life >100 hours, but pharmacodynamic effect correlates with DPP-4 inhibition rather than plasma levels.
Terminal elimination half-life is approximately 12.4 hours in patients with type 2 diabetes, supporting once-daily dosing. No accumulation occurs at steady state.
Empagliflozin: Approximately 95.6% excreted in feces (41.2% as unchanged drug) and 54.4% in urine (19.8% as unchanged). Linagliptin: 84% excreted in feces via enterohepatic circulation (80% as parent drug) and 5% in urine.
Approximately 65% of the dose is excreted in the urine as unchanged drug via active tubular secretion, and 35% is excreted in the feces as unchanged drug, indicating minimal metabolism.
Category C
Category C
SGLT2 Inhibitor/DPP-4 Inhibitor Combination Antidiabetic
SGLT2 Inhibitor